Prerpints.org logo
Preprint
Article

The Effect of High-Intensity Interval Exercise on Short-Term Glycaemic Control, Serum Level of Key Mediator in Hypoxia and Pro-Inflammatory Cytokines in Patients with Type 1 Diabetes

Altmetrics

Downloads

99

Views

32

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

05 August 2023

Posted:

08 August 2023

You are already at the latest version

Alerts
Abstract
Type 1 diabetes (T1D) is associated with hyperglycaemia-induced hypoxia and inflammation. The study assessed the effects of a single high-intensity interval exercise (HIIE) on glycaemia (BG) and serum level of pro-inflammatory cytokines and an essential mediator of adaptive response to hypoxia in T1D patients. The macronutrients intake was also evaluated. Nine patients suffering from T1D for about 12 years and nine healthy individuals (CG) were enrolled and completed one session of HIIE at the intensity of 120% lactate threshold and duration of 4 x 5 min intermittent with 5 min rest after each bout of exercise. Capillary and venous blood was withdrawn at rest, immediately after and at the 24 h post-HIIE for analysis of BG, hypoxia-inducible factor alpha (HIF-1α), tumour necrosis factor alpha (TNF-α) and vascular-endothelial growth factor (VEGF). Pre-exercise BG was significantly higher in the T1D compared to the CG (p = 0.043). HIIE led to a significant decline in T1D patients’ BG (p = 0.027) and to a tendency for a lower BG at 24-h post-HIIE vs pre-HIIE. HIF-1α was significantly elevated in the T1D compared to CG and there was a trend for HIF-1α to decline, and VEGF, TNF-α to increase in response to HIIE in the T1D group. Both groups consumed higher and lower than recommended amounts of protein and fat, respectively. In T1D group, a tendency for a higher digestible carbohydrate intake and more frequent hyperglycaemic episodes on the day after HIIE were observed. HIIE was effective in reducing T1D patients’ glycaemia and improving the short-term glycaemic control. HIIE has the potential to improve adaptive response to hypoxia by elevating the serum level of VEGF. Patients’ diet and level of physical activity should be screened on a regular basis, and they should be educated on the glycaemic effects of digestible carbohydrates.
Keywords: 
Subject: Biology and Life Sciences  -   Endocrinology and Metabolism

1. Introduction

Chronically elevated glycaemia in diabetes mellitus (DM) has been shown to induce a pro-inflammatory phenotype of endothelium and immune cells of primarily myeloid origin [1]. In a hyperglycaemic environment (fasting glycaemia > 125 mg/dL and 2-hour postprandial glycaemia > 180 mg/dL), macrophages, which are the main source of inflammatory cytokines, respond by enhanced secretion of mainly pro-inflammatory cytokines such as tumour necrosis factor alpha (TNF-α) [1,2]. TNF-α is a key pro-inflammatory cytokine, which is involved in systemic inflammation, but it also has an impact on physiological metabolic homeostasis such as glucose metabolism [3]. An abnormally elevated and sustained secretion of TNF-α is associated with autoimmune and other inflammatory diseases [4,5]. When compared to healthy individuals, increased levels of TNF-α have been found in individuals with newly diagnosed Type 1 diabetes (T1D) and the cytokine response has been shown to correlate positively with the disease duration, patient’s age [6]. TNF-α is also secreted by the endothelial cells in response to their persistent exposure to hyperglycaemia (HyperGl), which eventually leads to endothelial dysfunction (ED). ED is associated with reduced nitric oxide (NO) bioavailability and, consequently, reduced vasodilation, oxidative stress, increased permeability of the endothelial barrier and dysregulated expression of growth factors and pro-inflammatory cytokines, including TNF-α, vascular endothelial growth factor (VEGF), as well the transcription factor - hypoxia-inducible factor alpha (HIF-1α) [7,8,9]. ED initiates the development of micro- and macrovascular complications in T1D patients [10].
VEGF is an established stimulator of physiological and pathophysiological angiogenesis [11,12], whilst it also acts as a pro-inflammatory cytokine via increasing permeability of the endothelial barrier and by being chemotactic for monocytes [13,14]. The expression and activation of HIF-1α as a transcription factor, is regulated by hypoxia and glucose [15,16]. Hypoxia, which is defined as ‘insufficient cellular level of oxygen’, develops in most tissues of patients with T1D [17]. It has been proposed that HyperGl induces hypoxia in endothelial cells by elevating the rate of glycolysis, thus increasing the generation of mitochondrial ROS, which in turn, suppress the expression of the aquaporin – 1 (AQP-1) [18], a water channel that also facilitates oxygen diffusion across the cellular membrane [19]. The reduced expression of AQP-1 will lead to hypoxia and increased secretion of HIF-1α. Additionally, hypoxia in T1D can develop due to chronic exposure of blood cells, such as neutrophils and macrophages, to HyperGl which causes glycation of their protein molecules. This would adversely affect their structure and diapedesis ability, which in turn would cause the cells to plug the vessel lumen causing hypoxia of the endothelial cells [20].
Hyperglycaemia-induced chronic inflammation, sustained by the elevated levels of pro-inflammatory cytokines, leads to the development of life threating micro and macrovascular complications in both main types of DM [21,22]. Therefore, sufficient glycaemic control is of paramount importance in the management of T1D [23]. T1D treatment should not only consist of insulin therapy, but also adequate nutrition and regular physical exercise [24,25,26,27].
It has been shown that the knowledge or understanding of T1D dietary management is lacking [28], and not all T1D patients are aware that digestible (glycaemic) carbohydrates are fundamental macronutrients in influencing BG and insulin concentrations [29]. Foods such as potatoes, refined grains and those containing added sugars are harmful and have been linked to higher glycaemia, inflammation and cardiometabolic risk [30,31]. Furthermore, it has been shown that less than a fifth of adults with T1D manage to meet physical activity recommendations [32,33] despite evidence that regular physical activity in this population group provides many physiological and psychological benefits [34], whilst reducing daily insulin requirements [35].
When compared with moderate-intensity continuous training (MICT), the popularity of high-intensity interval single exercise (HIIE) and training (HIIT) has increased due to its time-saving characteristics, as well as the same, or even greater, effectiveness in improving cardiovascular risks factors in the sedentary, patients with coronary artery disease, heart failure and those with high cardiovascular risk [36,37,38,39,40]. HIIE has been shown to be effective in reducing glycaemia in T1D and T2D patients to a lower [41] or a greater [42] extent than MICT. Yet, it has also been demonstrated that HIIE can lead to an increase in glycaemia during or immediately after its completion in T1D patients [43]. This can be attributed to the higher release of counter-regulatory hormones, such as catecholamines, glucagon and cortisol [44]. Additionally, after the initial elevation in BG, there is a risk of a late-onset (up to 24-48 h post-exercise) hypoglycaemia, and therefore the fear of such often stops patients with T1D from exercising [41,45].
In this study, we aimed to assess the acute, and up to 24 h post-exercise effects of a single bout of HIIE on glycaemia and serum level of pro-inflammatory cytokines and a transcriptional factor that mediates response to hypoxia in T1D patients. In addition, we also evaluated the participants macronutrient intake and compared it against dietary recommendations for this population group.

2. Materials and Methods

2.1. Participants

Participants suffering from T1D for about 12 years (12.1 ± 6.0) were recruited at the Diabetes Clinic of the Silesian Centre in Poland and took part in the research project, which consisted of three stages, where the first two have already been published [46,47]. The current paper presents the findings of the third stage of the project, which was completed by eight participants with T1D (T1D group) (Figure 1).
All T1D participants adhered to intensive insulin (INS) therapy, where half of them were using continuous subcutaneous INS infusion (rapid-acting INS: Humalog, NovoRapid or Apidra) and the other half multiple daily INS injections with long-acting (Lantus or Levemir) and rapid-acting (NovoRapid) INS. The maximum glucose-lowering effect of all three rapid-acting types of INS occurs between 1 and 3 h and INS effect lasts 3–5 h. For the long-acting INS, the peak effect is observed after 6–14 h (Levemir only, with Lantus having no peak effect) and duration of action is between 16 and 20 (Levemir) and 20–24 h (Lantus) [48]. Only participants free of diabetic complications, with no history of other (not-diabetes related) or metabolic diseases were enrolled. The other inclusion criteria were as follows: no participation in another trial, having not had any acute infections up to 1 week prior to the study, being a non-smoker and having good exercise tolerance confirmed by the direct measurement of V̇O₂peak [46,47] and HbA1c < 8.0% (Table 1). The medical history and information about diabetes aetiology of the study participants were prepared by medical personnel of the Silesian Centre in Poland. The control group consisted of nine healthy individuals, without impaired glucose tolerance, and of a similar body composition (Table 1).
Prior to the study, the procedure and the related risks were explained to all potential participants prior to taking consent. They were also informed that the study was voluntary, and they could withdraw from it at any time without giving reasons. Written informed consent was obtained from all participants, and they were asked to abstain from exercise, the consumption of alcohol and caffeinated drinks 24 hours prior to the tests. Their diet, fasting glycemia and insulin dosage were monitored for the entire duration of the study. Composition of the diet was calculated with dedicated software (Dietus, B.U.I. InFit, Warszawa, Poland).

2.2. Study protocol.

All individuals were asked to arrive at the laboratory at least 2 hours after their breakfast. The T1D patients were asked to have their pre-exercise glycaemia within the range of 100-160 mg/dl and were advised to reduce their basal insulin infusion by 50% before the exercise tests. The participant’s body mass and composition were determined by means of Bioelectrical Impedance Analysis (BIA) (InBody 220 Data Management System, Biospace, Seoul, Korea).
The participants completed one high-intensity (120% lactate threshold: LAT, which was determined by the Dmax method [49] and corresponded to ≈ 90 ± 5% HRmax)) interval exercise session (HIIE: 4 x 5 min intermittent bouts with 5 min rest after each bout of exercise) at the laboratory with the ambient conditions of 21°C and 60% relative humidity.

2.3. Biochemical analyses.

Venous and capillary blood samples were taken from the cubital vein and a fingertip respectively, at rest (pre-HIIE), immediately after the cessation of HIIE (post-HIIE) and at the 24 h post-exercise.
Blood glucose concentration was measured in the capillary blood by enzymatic method (glucose dehydrogenase) (Glucose 201⁺, HemoCue, Sweden).
To measure the levels of selected pro-inflammatory cytokines: TNF-α and VEGF, as well as a transcription factor HIF-1α, venous blood samples were left to clot at the room temperature for 30 min and centrifuged for 15 min at 1000× g. The obtained serum was kept frozen at 80°C (for a period not longer than 8 months) without repeated freezing. Serum TNF-α was assessed using Immuno Assays, DIAsource, Belgium. The intra- and inter-assay coefficients of variation (CV) were 6.3 and 3.3%, respectively. Serum levels of HIF-1α and VEGF were measured by enzyme-linked immunosorbent assay ELISA kit (BlueGene Biotech Co., Ltd., Shanghai, China). The intra- and inter-assay coefficients of variations for HIF-1α and VEGF were <4.4% and <5.6%, respectively.
The T1DM patients were asked to record their BG, insulin dosages, and hypo- or hyperglycaemia events up to 24 h after the HIIE (patients’ diary). A BG value of < 70 mg/dL indicated hypoglycaemia (HypoGl) and a fasting BG value of > 125 mg/dL or 2-hour postprandial BG of > 180 mg/dL was diagnosed as HyperGl [50]. The percentage change in BG (% change) was calculated using the following equation:
% change = ((V₂-V₁))/(V₁) x 100
where:
V₁ represents the pre-HIIE value
V₂ represents the post-HIIE value

2.4. Statistical methods.

The statistical package (StatSoft Poland, 12.0) was used for data processing and analysis. The Shapiro–Wilk, Levene’s, and Mauchly’s tests were used to verify data normality, homogeneity, and sphericity respectively. Normally distributed data are presented as means and standard deviations. A one-way analysis of variance was used to compare the somatic variables between the studied groups and a two-way repeated measures ANOVA to verify the differences between the groups (T1D vs. control group) and HIIE (pre-HIIE vs post-HIIE). The effect size partial eta squared (η2) for the differences between the groups and pre- and post-HIIE was also calculated. The criteria to interpret the magnitude of the effect sizes (ES) were: <0.2 trivial, 0.2-0.6 small, 0.6-1.2 moderate, 1.2-2.0 large and >2.0 very large. The significance of the differences between the studied variables was verified with the Bonferroni post hoc test and p < 0.05 indicated statistical significance.

2.5. Ethics

The study protocol received an approval from the Ethics Committee of the Jerzy Kukuczka Academy of Physical Education in Katowice, Poland (the committee resolution number 3/2011; date of approval 26th October 2011) and conformed to the standards set by the Declaration of Helsinki.

3. Results

3.1. Participants’ somatic and physiological characteristics

There were no significant differences in body mass index (BMI), percentage of body fat (%BF) and fat-free mass (FFM) between the T1D and control group (Table 1). The mean %BF was low in both groups [51]. In T1D, one male participant was found with the %BF above the recommended for the age range (>22%) and his BMI indicated he was overweight. There was a non-significant tendency for age difference (p = 0.07) between the studied groups. The glycated haemoglobin (HbA1C), which reflects an average glycemia over approximately 3 months preceding the measurement, was above the recommended level (HbA1C < 7.0%) in 7 of 9 patients (78%) [23].
The assessment of aerobic fitness was based on V̇O2peak and considered age and gender [52]. The determination of V̇O2peak was assessed during stage 1 of the project [46]. In the T1D group, 33.3% (n = 3) of participants were found with a V̇O2 indicating poor, 44.4% excellent (n = 3) and 11% (n = 1) superior aerobic fitness, whilst the remaining participants had a good level of aerobic fitness. In the control group, one participant had poor, one had good, whilst 77.8% (n = 7) excellent and superior, levels of aerobic fitness.

3.2. Macronutrients intake.

The one-way ANOVA did not reveal any significant differences in the macronutrient intake between the studied groups, although there was a tendency for a lower carbohydrate and energy consumption in the T1D compared to the control group. Both groups consumed higher (> 20% energy intake) and lower (< 20% energy intake) than recommended [53] amounts of protein and fat, respectively.

3.3. Glycaemia in response to HIIE

There was a significant effect of group (T1D vs control group) on glycaemia (η2 = 0.50, p = 0.01) (ES = small). The post-hoc analysis revealed a significantly higher resting BG (BG rest) in the T1D compared to the control group (p = 0.04) and a significant decline in T1D patients’ BG in response to HIIE (pre-HIIE: 152.8±92.0 vs immediately post-HIIE: 90.0±55.7 mg/dL) (p = 0.03) and the BG % change was 41.11%. There was a tendency (p = 0.59) for a lower BG at 24-h post-HIIT in comparison with the pre-HIIE (123.5±52.0 vs 152.83±92.0 mg/dL, respectively) in T1D. In the control group, HIIE led to a slight decrease in the BG (%change 7.7%) (Figure 2).

3.4. Glycaemic control in 24-h post-exercise period

Based on the patients’ diary, fasting glycaemia, number of glycaemic disorders, insulin administration and intake of digestible carbohydrates (CHO; with exclusion of dietary fibre) were compared on the day of (day 1) and the day after (day 2) the HIIE (Table 2). ANOVA did not reveal a significant effect of the day on the above-mentioned variables. There was a tendency for a lower fasting glycaemia on day 2 compared to day 1, and a higher digestible CHO intake on day 2 in comparison with day 1 (Table 2). Hypoglycaemia developed at least once in 20% T1D patients on day 1 with the same % on day 2, whilst hyperglycaemic disorders were more frequent and developed (between 1- 4 times) in 60% of T1D patients on day 1 and 80% T1D on day 2.

3.5. HIF-1α, TNF-α and VEGF in response to HIIE

Table 3 presents the serum levels of the transcription factor HIF-1α the pro-inflammatory cytokines (TNF-α and VEGF) in response to HIIE.

3.5.1. HIF-1α

The ANOVA revealed a significant effect of the group on HIF-1α (η2 = 0.86, p = 0.01) (ES = moderate). Serum HIF-1α rest was significantly higher in the T1D compared to the control group (657.0 ± 210.4 vs 28.3 ± 11.5 ng/mL) (p = 0.01). There was a significant interaction effect (Group * HIIE) on HIF-1α (η2 = 0.65, p = 0.01) (ES = moderate) and a tendency for lower HIF-1α max (p = 0.13) and HIF-1α 24-h (p = 0.07) in comparison with HIF-1α rest in the T1D group (Table 2).
Preprints 81688 g003
Figure 3. HIF-1 alpha (α) serum level at rest, immediately after and at 24-h of post-exercise period in the T1D and control group.
Figure 3. HIF-1 alpha (α) serum level at rest, immediately after and at 24-h of post-exercise period in the T1D and control group.
Preprints 81688 g003

3.5.2. TNF-α

ANOVA showed a significant interaction effect (group * HIIE) on serum TNF-α (η2 = 0.56, p = 0.04) (ES = small). The post-hoc analysis did not reveal significant differences between the group or in response to HIIE. Only a tendency for a TNF-α increase in response to HIIE was seen in the T1D group, whereas TNF-α tended to decrease in the post-exercise period in healthy participants (Table 3). The resting levels of TNF-α tended to be slightly higher in the control vs T1D group.
Preprints 81688 g004
Figure 4. TNF-alpha (α) serum level at rest, immediately after and at 24-h of post-exercise period in the T1D and control group.
Figure 4. TNF-alpha (α) serum level at rest, immediately after and at 24-h of post-exercise period in the T1D and control group.
Preprints 81688 g004

3.5.3. VEGF

The ANOVA revealed a significant effect of the group (η2 = 0.75, p = 0.02) (ES = moderate) and an interaction effect (group * HIIE) η2 = 0.67, p = 0.01) (ES = moderate) on serum VEGF. VEGF max was significantly lower in the T1D compared to the control group (p = 0.02). There was also a tendency (p > 0.05) for lower resting levels of VEGF in T1D vs control group (Table 3).
Preprints 81688 g005
Figure 5. VEGF serum level at rest, immediately after and at 24-h of post-exercise period in the T1D and control group.
Figure 5. VEGF serum level at rest, immediately after and at 24-h of post-exercise period in the T1D and control group.
Preprints 81688 g005

4. Discussion

The acute and up to 24-hour effects of HIIE on glycaemia and the level of a transcriptional factor and selected pro-inflammatory cytokines was measured in patients with T1D with moderate glycaemic control [23] and healthy individuals. The major finding of this study is that HIIE significantly reduced patients’ BG to a safe level and there was a tendency for lower BG in the 24 h post-exercise compared to the baseline BG. HIIE did not lead to significant changes, although there was a tendency for lower HIF-1α and increased VEGF immediately after HIIE and at the 24 h post-exercise. There was also a tendency for TNF-α to increase in response to HIIE in the T1D group only.
Glycaemia control in T1D is a constant challenge and patients with T1D are at increased risk of acute and chronic diabetes-related complications. In addition to insulin therapy, an appropriate diet and regular exercise can help patients manage their glycaemia more efficiently [24,32]. However, some individuals with T1D choose not to exercise due to the increased probability of experiencing a hypoglycaemic event [41,54], or for other reasons, which can be seen as typical barriers to exercise, such as laziness [55], stressful work conditions or lack of discipline [56], or a misunderstanding in terms of its effectiveness [57]. The intensity of any exercise undertaken is an important consideration in T1D, and there is evidence to show that HIIE reduces the risk of hypoglycaemia when compared to moderate continuous exercise [58,59]. This could be explained by greater reliance on intramuscular glycogen and phosphagens over blood glucose as an energy source [60], as well as augmented gluconeogenesis [61].
Our study findings confirm the effectiveness of HIIE in reducing glycaemia in T1D patients, as a significant BG reduction was observed immediately after HIIE. In addition, the beneficial effect of HIIE seemed to be maintained until the next day as there was a tendency for lower fasting BG in the T1D group. Nevertheless, T1D patients experienced more episodes of HyperGl on the day following rather than on the day of HIIE (day 2 vs day 1), which could have been associated with a tendency for a higher glycaemic CHO intake on day 2 (190.5±57.7 g/day) compared to day 1 (157.0±104.2 g/day). In another study, HIIE consisting of a 10-min warm-up followed by 10-sec sprints every 2 minutes for 24 minutes and then an 11-min cool-down performed in a fasting vs postprandial state resulted in a different BG trajectory [62]. As seen in our study, the postprandial HIIE significantly reduced glycaemia (pre- vs immediately post-exercise) in T1D patients and this glycaemia lowering effect was maintained for 24 h. Fasting HIIE, on the other hand, led to an increase in BG, where the authors speculated that such a difference could have been associated with the dawn phenomenon and a greater secretion of growth hormone in the morning, having a lipolysis-enhancing, and hence, glucose-sparing effect during the morning HIIE [63,64] . In our study, the participants performed the HIIE in a post-prandial state and HypoGl developed at least once (the participants monitored their glycaemia at a varied frequency) in 20% of T1D patients on the day after completing HIIE, with the same percentage of occurrence the following day. Yardley [62] suggested performing HIIE in a fasted state may be beneficial to avoid HypoGl during exercise. In a case study, conducted by Cockroft et al. [65] HIIE consisting of 3 min warm up at 20 W, eight bouts of 1 min cycling at 90% of peak power interspersed with 1.25 min recovery at 20 W, followed by a 3 min cool down at 20 W, caused a drop in BG in two out of three adolescents with T1D and led to a lower average glycaemia in the 24-h post-exercise period; a finding also observed in our study. The authors compared the glycaemic effects of HIIE vs. moderate intensity exercise (MIE) and concluded that both HIIE and MIE had the potential to improve short-term glycaemia control in young individuals with T1D, but HIIE was more enjoyable to perform [59,65].
It has been demonstrated that for overall glycaemic control to be improved, a skilful balance of insulin dosing and consumption of food, especially glycaemic CHO, before, during and after exercise is required from T1D patients [66,67]. In our study, it seemed that the fear of HypoGl in the post-exercise period led to a greater intake of such CHO. In our opinion, patients with T1D would benefit from knowing what types of CHO should be consumed in the post-exercise period to reduce the frequency of glycaemic disorders, both hypo- and hyperglycaemic. This would also help to improve the long-term glycaemic control and maintain the HbA1C at the recommended level (HbA1C < 7.0%) to reduce the risk of diabetes-related complications [23]. It has been shown that even a 0.2% reduction in HbA1C, albeit slight, reduces cardiovascular risk by 10% [68]. In our study, the baseline HbA1C was > 7.0% in the majority of T1D participants (78%; 7 out of 9) although it was 8.9% in one participant, which indicated poor glycaemic control [23].
The studies have shown that low glycaemic index (GI) and glycaemic load (GL) diets improve glycaemic control in T1D and T2D, with more studies being conducted on the latter [69]. Jenkins et al. [70] demonstrated that a 3-month low-GI diet (with a high content of legumes or fibre) improved glycaemic control in adult T2D patients. Similarly, a long-term dietary treatment (20% protein, 30% fat, and 50% CHO) with increased amounts of fibre-rich (50 g/day) and low GI natural foods improved glycaemia control and decreased the number of hypoglycaemic events in T1D patients [71]. In our study, participants with T1D consumed similar total (glycaemic and non-glycaemic) CHO (54% of total energy intake), however we did not analyse their fibre intake, which makes this comparison unreliable. The total CHO of about 54% of daily energy intake was within the European Association for the Study of Diabetes dietary recommendations (45-60%) [72]. However, two T1D individuals consumed larger amounts of CHO (> 70% of total energy intake) and this seemed to have influenced their HbA1c, which was significantly above the recommended level (HbA1c < 7.0%) in one of these participants (HbA1c = 8.9%) [23]. This finding shows that an excessive intake of CHO has a significant impact on glycaemic control, however, insufficient glucose monitoring and insulin administration, as well as physical activity level could have also contributed to this finding. Overall, the T1D participants consumed fewer CHO in comparison with the control group, however the difference was insignificant. The diet of the control group also consisted of a larger amount of glycaemic CHO, such as potatoes and bread when compared with T1D patients. Post-prandial glycaemia following a carbohydrate-rich meal, and the resultant insulinaemia, have been implicated in the aetiology of cardiovascular disease and T2D, hence it seems reasonable to assume that lower to moderate intake of glycaemic CHO may protect from the development of such diseases in healthy people [74]. The ideal amount of CHO in the diet of patients with T1D is still unclear [75]. Studies in the U.S. have shown that most individuals with T1D and T2D report consuming moderate amounts of carbohydrate (~45% of total energy intake) [76], which is lower than in the present study.
Fat is a macronutrient that can influence glycaemia as co-ingestion of fat with CHO slows down gastric emptying and in turn, the release of glucose into the blood which ultimately reduces BG [74]. In our study, both groups consumed low amounts of fat (both saturated and unsaturated) i.e. 19.4% of total energy intake. Similarly, data on the ideal total dietary fat content for people with T1D seems to be inconclusive (30-35% of total energy intake for general population [77]), but a Mediterranean-style diet that is rich in monounsaturated and polyunsaturated fats has been shown to improve glucose metabolism and be more beneficial than a low-fat high-carbohydrate diet [78,79].
Protein intake also affects glycaemia as, similarly to fat, its ingestion slows down gastric emptying, and hence glucose release into the bloodstream [80]. With research being inconclusive as to the ideal amount of dietary protein to optimise glycaemic control and/or cardiovascular disease risk in DM, protein intake goals should follow that of the general population (10-15% of total energy intake) [77,81] or there may be the need for them to be individualised in certain cases [75]. Those with diabetic kidney disease should aim to consume no more than 0.8 g/kg body mass/day [82]. In our study, T1D group consumed more protein than this (116.2±58.4 g/day; 1.6±0.8 g/kg/day; ~ 20% of total energy intake) as did the control group, yet participants did not have albuminuria or reduced estimated glomerular filtration rate. It is worth noting that certain amount of protein consumed is converted into BG in the process of gluconeogenesis, nevertheless its effect on BG seems to be relatively small [80].
The fact that there was low fat and high protein intake in both groups, with excessive intake of glycaemic CHO in some T1D individuals and most of the control group participants, deserves some attention. Dietary guidelines for T1D patients, including what to consume before and after exercise, do not seem to be fully established yet and this requires exploration. We propose that in addition to regular health checks related to DM, the diets of T1D patients, as well as the level of physical activity, should be screened on a regular basis to improve glycaemic control and prevent the development of chronic complications.
As T1D is associated with impaired adaptive response to hypoxia, a common feature of T1D [17], and with chronic inflammation leading to the development of micro- and macrovascular complications [23], we also measured the effect of HIIE on the serum levels of selected pro-inflammatory cytokines, TNF-α and VEGF and of the main regulator of response to hypoxia, HIF-1α.
T1D had a significant effect on HIF-1α, as its resting serum levels were 20-fold higher in the T1D group compared to healthy participants. This finding confirms a stimulatory effect of hyperglycaemia-induced hypoxia on the expression of HIF-1α [15,16], as under normoxic conditions HIF-1α has an extremely short half-life of less than five minutes as it is continuously synthesized and degraded [84]. The HIIE led to a 34.4% and 39.1% decline in the level of HIF-1α immediately and at 24 h after completion of HIIE, respectively. Conversely, in the control group, HIF-1α increased over 2-fold in response to HIIT, which confirms that high intensity exercise induces hypoxia and enhances the stability, thus serum level of HIF-1α [85]. The decreasing trend for HIF-1α in T1D patients may be associated with the BG decline in response to HIIE and confirms that better glycaemic control is crucial and may diminish cellular hypoxia and reduce inflammation, since HIF-1α also regulates the expression of the genes coding for pro-inflammatory cytokines: TNF-α and VEGF [86]. Li et al. [87] also observed elevated serum levels of HIF-1α in patients with T2D compared to healthy individuals, however, the mean HIF-1α concentration was substantially lower than that observed in our study (0.2±0.1 ng/mL vs 657.0±210.4 ng/mL, respectively). Additionally, the T2D patients with coronary artery calcification were found to have significantly higher HIF-1α levels compared to those without, and HIF-1α correlated positively with HbA1c and other factors of inflammation (CRP, IL-6) [87], which makes HIF-1α a good candidate for a marker of inflammation and glycaemic control in DM. Rusdiana et al. [88] also demonstrated lower levels of HIF-1α in patients with T2D compared to what was observed in the current study (1.7 ± 0.6 ng/ml vs 657.0±210.4 ng/mL, respectively). The difference between HIF-1α serum levels in T1D vs T2D could be explained by a more severe and more frequent HyperGl episodes in T1D patients and consequently, greater HyperGl-induced expression of HIF-1α [15,16]. Studies demonstrating serum concentration of HIF-1α in humans with T1D seem to be lacking, but a few in vitro studies have shown augmented expression and stability of HIF-1α in cultured human retinal pigment epithelium [89]. Nevertheless, the majority of in vitro studies have concluded that hyperglycaemia is responsible for reduced HIF-1α stability and compromised transcriptional activation function via impaired interaction with the transcriptional coactivator p300 [90]. Thangarajah et al. [91], on the other hand, demonstrated that only HIF-1α activity, not stability, is impaired in the high glucose environment (hyperglycemic culture).
One of HIF-1α target genes is VEGF, which acts as a pro-inflammatory and pro-angiogenic cytokine, which is essential for postnatal neovascularisation [91,92]. In our study, the pre-exercise levels of VEGF tended to be lower in the T1D compared to the control group, which suggests impaired transcriptional activity of HIF-1α as demonstrated by Thangarajah et al. [91]. Interestingly, VEGF tended to increase in response to HIIE and this observation was accompanied by decreasing levels of HIF-1α. It has been previously demonstrated that not only HIF-1α, but also vascular sheer stress during exercise can stimulate the expression of VEGF [93]. Moreover, Arany et al. [94] showed that the transcriptional coactivator PGC-1alpha (peroxisome-proliferator-activated receptor-gamma coactivator-1alpha), a major regulator of mitochondrial function in response to exercise or other situations characterised by a lack of oxygen and nutrients, stimulates VEGF expression via an HIF-1α independent pathway in cultured muscle cells and skeletal muscle in vivo. In the present study, we did not measure the level of PGC-1α, and therefore we can only speculate that its expression increased in response to HIIE and contributed to the elevated VEGF in the T1D group. In the control group, on the other hand, VEGF tended to decrease in response to HIIE. VEGF expression has been found to be dysregulated in various tissues of T1D patients. The angiogenic paradox, where angiogenesis is either insufficient in myocardium, nerves, skeletal muscle and skin, or excessive in retina, is a phenomenon that can occur in the same patient with T1D [95,96,97]. Since inadequate collateral blood vessel formation in response to hypoxia and reduced wound healing increases cardiovascular morbidity and mortality, and the risk of amputations respectively, the observation tendency for VEGF to increase in response to HIIE, as noted in our study, with its level staying elevated at the 24h seems to be a beneficial observation in patients with T1D, in whom angiogenesis may be insufficient. On the other hand, VEGF is also a pro-inflammatory cytokine, and its elevated levels indicate inflammation. However, acute inflammation following a bout of exercise leads to regeneration of the damaged myocytes as an adaptation to exercise [98].
VEGF expression has been shown to be also stimulated by TNF-α [99]. In T1D group, TNF-α tended to increase and in the control group to decrease in response to HIIE. In another study in healthy and T2D individuals, serum levels of TNF-α did not change in response to exercise of a longer duration (25 min) and lower intensity (60%V̇O2max) compared to our exercise intervention. There was also no difference between the resting and post-exercise levels of the cytokine between the studied groups that were age, gender, V̇O2peak, weight and body mass index-matched [100]. In our study, the T1D patients were found to have a 2-fold lower pre-exercise levels of TNF-α compared to the control group, but the difference was not significant. TNF-α is a biomarker of systemic inflammation [3,4,5], therefore the fact that its level was lower in the T1D group could indicate no chronic inflammation. Nevertheless, this observation is based on the mean value and 22.2% of T1D participants (n = 2) were found with resting TNF-α of > 50.0 pg/mL, which indicated a rather high level of inflammation when compared with the normal range of the cytokine observed in individuals without inflammatory diseases [101,102]. TNF-α is amongst the main pro-inflammatory cytokines implicated in the inflammation of the pancreatic beta cells [103], hence its elevated level is to be expected in T1D patients. Additionally, we cannot rule out the effects that the previous exercise sessions may have had on the TNF-α results, although as the sessions were seven days apart this is unlikely. The decrease in TNF-α response to HIIE observed in the control group could be explained by a higher level of aerobic fitness (based on V̇O2peak) and greater adaptation to high intensity exercise of the healthy individuals compared to the T1D group, and hence a diminished inflammatory response to a single exercise session [98].

5. Conclusions

In conclusion, our study demonstrates that a single high-intensity exercise is effective in reducing glycaemia of patients with T1D to a safe level and in improving a short-term glycaemic control. An excessive intake of digestible carbohydrates in post-exercise period (24 hours after the exercise) diminishes the glycaemia-lowering effect of the exercise but it is driven by the fear of hypoglycaemia. Diabetes was associated with abnormally elevated serum levels of the main mediator of adaptive response to hypoxia (HIF-1α), which develops in hyperglycaemic environment that impairs its transcriptional activity. The high-intensity interval exercise led to an increase in the main stimulator of angiogenesis (VEGF), which could indicate an improved adaptive response in hypoxic tissues in patients with T1D, the increase was, however, insignificant. The study also highlights the need for T1D patients’ physical activity level and diet assessment, and education to explain the type and amount carbohydrates that should be consumed post-exercise to minimise the frequency of acute glycaemic disorders that over time lead to the development of diabetes-related complications. This section is not mandatory but can be added to the manuscript if the discussion is unusually long or complex.

6. Limitations

Our study has several limitations. Due to challenges in recruiting the patients with T1D who are willing to participate in our study, the sample size is small. Additionally, there are some differences in the age and level of aerobic fitness between the T1D and control group. Also, the intensive insulin therapy and different types of insulin and methods of its administration could have affected the glycaemic response to the exercise intervention in the T1D group. Moreover, we did not measure the concentrations of the counterregulatory hormones (noradrenaline, adrenaline, cortisol, growth hormone), which further impedes the interpretation of the HIIE effects. Finally, the serum concentrations of HIF-1α, TNF-α and VEGF were assessed immediately after and at the 24 h post-exercise, which limits the ability to draw conclusions about the long-term therapeutic effects.

Author Contributions

Conceptualization and methodology, A.Ż. and B.H.; software, M.S.; validation, A.Ż. and B.H.; formal analysis, M.S.; investigation, B.H. and A.Ż.; resources, S.S.; data curation, M.S. and S.S.; writing—original draft preparation, B.H.; writing—review and editing, A.R.; visualization, M.S.; supervision, A.Ż.; project administration, A.Ż. and B.H.; funding acquisition, A.Ż. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Jerzy Kukuczka Academy of Physical Education in Katowice, Poland (the committee resolution number 3/2011; date of approval 26th October 2011).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The datasets used are available from the corresponding author upon request.

Acknowledgments

The authors appreciate the physicians’ and nurses’ help in implementing the study and would like to thank all study participants.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Moganti, K.; Li, F.; Schmuttermaier, C.; Riemann, S.; Klüter, H.; Gratchev, A.; Harmsen, M.C.; Kzhyshkowska, J. Hyperglycemia induces mixed M1/M2 cytokine profile in primary human monocyte-derived macrophages. Immunobiology 2017, 222, 952–959. [Google Scholar] [CrossRef] [PubMed]
  2. Torres-Castro, I.; Arroyo-Camarena, D.; Martínez-Reyes, C.P.; Gómez-Arauz, A.Y.; Dueñas-Andrade, Y.; Hernández-Ruiz, J.; Béjar, Y.L.; Zaga-Clavellina, V.; Morales-Montor, J.; Terrazas, L.I.; et al. Human monocytes and macrophages undergo M1-type inflammatory polarization in response to high levels of glucose. Immunol. Lett. 2016, 176, 81–89. [Google Scholar] [CrossRef] [PubMed]
  3. Sethi, J.K.; Hotamisligil, G.S. Metabolic Messengers: tumour necrosis factor. Nat. Metab. 2021, 3, 1302–1312. [Google Scholar] [CrossRef] [PubMed]
  4. Crespo, J.; Cayón, A.; Fernández-Gil, P.; Hernández-Guerra, M.; Mayorga, M.; Domínguez-Díez, A.; Fernández-Escalante, J.C.; Pons-Romero, F. Gene expression of tumor necrosis factor [alpha ] and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001, 34, 1158–1163. [Google Scholar] [CrossRef]
  5. Kugelmas, M.; Hill, D.B.; Vivian, B.; Marsano, L.; McClain, C.J. Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003, 38, 413–419. [Google Scholar] [CrossRef]
  6. Mohamed-Ali, V.; Armstrong, L.; Clarke, D.; Bolton, C.H.; Pinkney, J.H. Evidence for the regulation of levels of plasma adhesion molecules by proinflammatory cytokines and their soluble receptors in type 1 diabetes. J. Intern. Med. 2001, 250, 415–421. [Google Scholar] [CrossRef]
  7. Al-Isa, A.N.; Thalib, L.; Akanji, A.O. Circulating markers of inflammation and endothelial dysfunction in Arab adolescent subjects: Reference ranges and associations with age, gender, body mass and insulin sensitivity. Atherosclerosis 2010, 208, 543–549. [Google Scholar] [CrossRef]
  8. Popov, D. Endothelial cell dysfunction in hyperglycemia: Phenotypic change, intracellular signaling modification, ultrastructural alteration, and potential clinical outcomes. Int. J. Diabetes Mellit. 2010, 2, 189–195. [Google Scholar] [CrossRef]
  9. Haidari, M.; Zhang, W.; Willerson, J.T.; Dixon, R.A. Disruption of endothelial adherens junctions by high glucose is mediated by protein kinase C-β–dependent vascular endothelial cadherin tyrosine phosphorylation. Cardiovasc. Diabetol. 2014, 13, 105–105. [Google Scholar] [CrossRef]
  10. Domingueti, C.P.; Dusse, L.M.S.; Carvalho, M.d.G.; de Sousa, L.P.; Gomes, K.B.; Fernandes, A.P. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J. Diabetes its Complicat. 2016, 30, 738–745. [Google Scholar] [CrossRef]
  11. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1, 27–30. [Google Scholar] [CrossRef] [PubMed]
  12. Ferrara, N.; Davis-Smyth, T. The Biology of Vascular Endothelial Growth Factor. Endocr. Rev. 1997, 18, 4–25. [Google Scholar] [CrossRef]
  13. Melder, R.J.; Koenig, G.C.; Witwer, B.P.; Safabakhsh, N.; Munn, L.L.; Jain, R.K. During angiogenesis, vascular endothelial growth factor regulate natural killer cell adhesion to tumor endothelium. Nat. Med. 1996, 2, 992–997. [Google Scholar] [CrossRef] [PubMed]
  14. Barleon, B.; Sozzani, S.; Zhou, D.; Weich, H.; Mantovani, A.; Marme, D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996, 87, 3336–3343. [Google Scholar] [CrossRef] [PubMed]
  15. Vordermark, D.; Kraft, P.; Katzer, A.; Bölling, T.; Willner, J.; Flentje, M. Glucose requirement for hypoxic accumulation of hypoxia-inducible factor-1α (HIF-1α). Cancer Lett. 2005, 230, 122–133. [Google Scholar] [CrossRef]
  16. Staab, A.; Löffler, J.; Said, H.M.; Katzer, A.; Beyer, M.; Polat, B.; Einsele, H.; Flentje, M.; Vordermark, D. Modulation of Glucose Metabolism Inhibits Hypoxic Accumulation of Hypoxia-Inducible Factor-1α (HIF-1α). Strahlenther Onkol 2007, 183, 366–373. [Google Scholar] [CrossRef]
  17. Catrina, S.-B.; Zheng, X. Hypoxia and hypoxia-inducible factors in diabetes and its complications. Diabetologia 2021, 64, 709–716. [Google Scholar] [CrossRef]
  18. Sada, K.; Nishikawa, T.; Kukidome, D.; Yoshinaga, T.; Kajihara, N.; Sonoda, K.; Senokuchi, T.; Motoshima, H.; Matsumura, T.; Araki, E. Hyperglycemia Induces Cellular Hypoxia through Production of Mitochondrial ROS Followed by Suppression of Aquaporin-1. PLOS ONE 2016, 11, e0158619. [Google Scholar] [CrossRef]
  19. Echevarría, M.; Muñoz-Cabello, A.M.; Sánchez-Silva, R.; Toledo-Aral, J.J.; López-Barneo, J. Development of Cytosolic Hypoxia and Hypoxia-inducible Factor Stabilization Are Facilitated by Aquaporin-1 Expression. J. Biol. Chem. 2007, 282, 30207–30215. [Google Scholar] [CrossRef]
  20. Sugano, R.; Matsuoka, H.; Haramaki, N.; Umei, H.; Murase, E.; Fukami, K.; Iida, S.; Ikeda, H.; Imaizumi, T. Polymorphonuclear Leukocytes May Impair Endothelial Function. Arter. Thromb. Vasc. Biol. 2005, 25, 1262–1267. [Google Scholar] [CrossRef]
  21. Kennedy, L.; Baynes, W. Non-enzymatic glycosylation and the chronic complications of diabetes: an overview. Diabetologia 1984, 26, 93–98. [Google Scholar] [CrossRef] [PubMed]
  22. Campos, C. Chronic Hyperglycemia and Glucose Toxicity: Pathology and Clinical Sequelae. Postgrad. Med. 2012, 124, 90–97. [Google Scholar] [CrossRef] [PubMed]
  23. American Diabetes Association Professional Practice Committee 6. Glycemic Targets: Standards of Medical Care in Diabetes—2022. Diabetes Care 2021, 45 (Suppl. 1), S83–S96. [Google Scholar] [CrossRef]
  24. World Health Organization, Global Report on Diabetes. 2016. Available online: http://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf?sequence=1&isAllowed=y) (accessed on 26 January 2022).
  25. Pedersen, B.K.; Saltin, B. Exercise as medicine–Evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand. J. Med. Sci. Sports 2015, 25 (Suppl. S3), 1–72. [Google Scholar] [CrossRef]
  26. Reddy, R.; Wittenberg, A.; Castle, J.R.; El Youssef, J.; Winters-Stone, K.; Gillingham, M.; Jacobs, P.G. Effect of Aerobic and Resistance Exercise on Glycemic Control in Adults With Type 1 Diabetes. Can. J. Diabetes 2018, 43, 406–414.e1. [Google Scholar] [CrossRef]
  27. Colberg, R. Nutrition and Exercise Performance in Adults with Type 1 Diabetes. Can J Diabetes 2020, 44, 750–758. [Google Scholar] [CrossRef]
  28. Pancheva, R.; Zhelyazkova, D.; Ahmed, F.; Gillon-Keren, M.; Usheva, N.; Bocheva, Y.; Boyadzhieva, M.; Valchev, G.; Yotov, Y.; Iotova, V. Dietary Intake and Adherence to the Recommendations for Healthy Eating in Patients With Type 1 Diabetes: A Narrative Review. Front. Nutr. 2021, 8, 782670. [Google Scholar] [CrossRef]
  29. Meyer, K.A.; Kushi, L.H.; Jacobs, D.R., Jr.; Slavin, J.; Sellers, T.A.; Folsom, A.R. Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. Am. J. Clin. Nutr. 2000, 71, 921–930. [Google Scholar] [CrossRef]
  30. Khosravi-Boroujeni, H.; Saadatnia, M.; Shakeri, F.; Keshteli, A.H.; Esmaillzadeh, A. A case-control study on potato consumption and risk of stroke in central Iran. . 2013, 16. [Google Scholar]
  31. Mozaffarian, D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review. Circulation 2016, 133, 187–225. [Google Scholar] [CrossRef]
  32. Bohn, B.; Herbst, A.; Pfeifer, M.; Krakow, D.; Zimny, S.; Kopp, F.; Melmer, A.; Steinacker, J.M.; Holl, R.W. Impact of Physical Activity on Glycemic Control and Prevalence of Cardiovascular Risk Factors in Adults With Type 1 Diabetes: A Cross-sectional Multicenter Study of 18,028 Patients. Diabetes Care 2015, 38, 1536–1543. [Google Scholar] [CrossRef] [PubMed]
  33. Sikora, M.; Zwierzchowska, A.; Jaworska, M.; Solich-Talanda, M.; Mikolajczyk, R.; Zebrowska, A. The effects of physical activity on glycaemic control in children and adolescents with type 1 diabetes mellitus participating in diabetes camp. Balt. J. Heal. Phys. Act. 2018, 10, 151–161. [Google Scholar] [CrossRef]
  34. Miller, R.G.; Mahajan, H.D.; Costacou, T.; Sekikawa, A.; Anderson, S.J.; Orchard, T.J. A Contemporary Estimate of Total Mortality and Cardiovascular Disease Risk in Young Adults With Type 1 Diabetes: The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2016, 39, 2296–2303. [Google Scholar] [CrossRef] [PubMed]
  35. Kennedy, A.; Nirantharakumar, K.; Chimen, M.; Pang, T.T.; Hemming, K.; Andrews, R.C.; Narendran, P. Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. PLOS ONE 2013, 8, e58861. [Google Scholar] [CrossRef] [PubMed]
  36. DiPietro, L.; Dziura, J.; Yeckel, C.W.; Neufer, P.D. Exercise and improved insulin sensitivity in older women: evidence of the enduring benefits of higher intensity training. J. Appl. Physiol. 2006, 100, 142–149. [Google Scholar] [CrossRef]
  37. O’donovan, G.; Kearney, E.M.; Nevill, A.M.; Woolf-May, K.; Bird, S.R. The effects of 24 weeks of moderate- or high-intensity exercise on insulin resistance. Eur. J. Appl. Physiol. 2005, 95, 522–528. [Google Scholar] [CrossRef] [PubMed]
  38. O'Donovan, G.; Owen, A.; Bird, S.R.; Kearney, E.M.; Nevill, A.M.; Jones, D.W.; Woolf-May, K. Changes in cardiorespiratory fitness and coronary heart disease risk factors following 24 wk of moderate- or high-intensity exercise of equal energy cost. J. Appl. Physiol. 2005, 98, 1619–1625. [Google Scholar] [CrossRef]
  39. Guiraud, T.; Nigam, A.; Gremeaux, V.; Meyer, P.; Juneau, M.; Bosquet, L. High-Intensity Interval Training in Cardiac Rehabilitation. Sports Med. 2012, 42, 587–605. [Google Scholar] [CrossRef] [PubMed]
  40. Štajer, V.; Milovanović, I.M.; Todorović, N.; Ranisavljev, M.; Pišot, S.; Drid, P. Let's (Tik) Talk About Fitness Trends. Front. Public Heal. 2022, 10, 899949. [Google Scholar] [CrossRef]
  41. Moser, O.; Tschakert, G.; Mueller, A.; Groeschl, W.; Pieber, T.R.; Obermayer-Pietsch, B.; Koehler, G.; Hofmann, P. Effects of High-Intensity Interval Exercise versus Moderate Continuous Exercise on Glucose Homeostasis and Hormone Response in Patients with Type 1 Diabetes Mellitus Using Novel Ultra-Long-Acting Insulin. PLOS ONE 2015, 10, e0136489. [Google Scholar] [CrossRef]
  42. Mitranun, W.; Deerochanawong, C.; Tanaka, H.; Suksom, D. Continuous vs interval training on glycemic control and macro- and microvascular reactivity in type 2 diabetic patients. Scand. J. Med. Sci. Sports 2013, 24, e69–e76. [Google Scholar] [CrossRef]
  43. Yardley, J.E.; Kenny, G.P.; Perkins, B.A.; Riddell, M.C.; Balaa, N.; Malcolm, J.; Boulay, P.; Khandwala, F.; Sigal, R.J. Resistance Versus Aerobic Exercise. Diabetes Care 2013, 36, 537–542. [Google Scholar] [CrossRef] [PubMed]
  44. Sandoval, D.A.; Guy, D.L.A.; Richardson, M.A.; Ertl, A.C.; Davis, S.N. Effects of Low and Moderate Antecedent Exercise on Counterregulatory Responses to Subsequent Hypoglycemia in Type 1 Diabetes. Diabetes 2004, 53, 1798–1806. [Google Scholar] [CrossRef]
  45. Younk, L.M.; Mikeladze, M.; Tate, D.; Davis, S.N. Exercise-related hypoglycemia in diabetes mellitus. Expert Rev. Endocrinol. Metab. 2011, 6, 93–108. [Google Scholar] [CrossRef]
  46. Żebrowska, A.; Hall, B.; Kochańska-Dziurowicz, A.; Janikowska, G. The effect of high intensity physical exercise and hypoxia on glycemia, angiogenic biomarkers and cardiorespiratory function in patients with type 1 diabetes. Adv. Clin. Exp. Med. 2018, 27, 207–216. [Google Scholar] [CrossRef]
  47. Żebrowska, A.; Sikora, M.; Konarska, A.; Zwierzchowska, A.; Kamiński, T.; Robins, A.; Hall, B. Moderate intensity exercise in hypoxia increases IGF-1 bioavailability and serum irisin in individuals with type 1 diabetes. Ther. Adv. Endocrinol. Metab. 2020, 11, 1. [Google Scholar] [CrossRef]
  48. Hirsch, I.B. Insulin Analogues. New Engl. J. Med. 2005, 352, 174–183. [Google Scholar] [CrossRef] [PubMed]
  49. Cheng, B.; Kuipers, H.; Snyder, A.C.; Keizer, H.A.; Jeukendrup, A.; Hesselink, M. A New Approach for the Determination of Ventilatory and Lactate Thresholds. Int. J. Sports Med. 1992, 13, 518–522. [Google Scholar] [CrossRef]
  50. American Diabetes Association Professional Practice Committee 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:Standards of Medical Care in Diabetes—2022. Diabetes Care 2021, 45, S60–S82. [Google Scholar] [CrossRef]
  51. Tanita. Understanding your measurements. Available online: https://tanita.eu/understanding-your-measurements (accessed on 13 July 2023).
  52. Heyward, V.H. Advanced Fitness Assessment and Exercise Prescription. Med. Sci. Sports Exerc. 1992, 24, 278. [Google Scholar] [CrossRef]
  53. Jarosz, M.; Rychlik, E.; Stoś, K.; Charzewska, J. Normy Żywienia Dla Populacji Polski I Ich Zastosowanie; Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny: Warszawa, Poland, 2020; ISBN 9788365870285. [Google Scholar]
  54. Codella, R.; Terruzzi, I.; Luzi, L. Why should people with type 1 diabetes exercise regularly? Acta Diabetol. 2017, 54, 615–630. [Google Scholar] [CrossRef] [PubMed]
  55. Oja, L.; Piksööt, J. Physical Activity and Sports Participation among Adolescents: Associations with Sports-Related Knowledge and Attitudes. Int. J. Environ. Res. Public Heal. 2022, 19, 6235. [Google Scholar] [CrossRef] [PubMed]
  56. Adamsen, L.; Andersen, C.; Lillelund, C.; Bloomquist, K.; Møller, T. Rethinking exercise identity: a qualitative study of physically inactive cancer patients’ transforming process while undergoing chemotherapy. BMJ Open 2017, 7, e016689. [Google Scholar] [CrossRef] [PubMed]
  57. McKevitt, S.; Jinks, C.; Healey, E.L.; Quicke, J.G. The attitudes towards, and beliefs about, physical activity in people with osteoarthritis and comorbidity: A qualitative investigation. Musculoskelet. Care 2021, 20, 167–179. [Google Scholar] [CrossRef]
  58. Hasan, S.; Shaw, S.M.; Gelling, L.H.; Kerr, C.J.; A Meads, C. Exercise modes and their association with hypoglycemia episodes in adults with type 1 diabetes mellitus: a systematic review. BMJ Open Diabetes Res. Care 2018, 6, e000578. [Google Scholar] [CrossRef]
  59. Alarcón-Gómez, J.; Chulvi-Medrano, I.; Martin-Rivera, F.; Calatayud, J. Effect of High-Intensity Interval Training on Quality of Life, Sleep Quality, Exercise Motivation and Enjoyment in Sedentary People with Type 1 Diabetes Mellitus. Int. J. Environ. Res. Public Heal. 2021, 18, 12612. [Google Scholar] [CrossRef]
  60. Petersen, K.F.; Price, T.B.; Bergeron, R. Regulation of Net Hepatic Glycogenolysis and Gluconeogenesis during Exercise: Impact of Type 1 Diabetes. J. Clin. Endocrinol. Metab. 2004, 89, 4656–4664. [Google Scholar] [CrossRef]
  61. Riddell, M.C.; Gallen, I.W.; Smart, C.E.; Taplin, C.E.; Adolfsson, P.; Lumb, A.N.; Kowalski, A.; Rabasa-Lhoret, R.; McCrimmon, R.J.; Hume, C.; et al. Exercise management in type 1 diabetes: A consensus statement. Lancet Diabetes Endocrinol. 2017, 5, 377–390. [Google Scholar] [CrossRef]
  62. Yardley, J.E. Fasting May Alter Blood Glucose Responses to High-Intensity Interval Exercise in Adults With Type 1 Diabetes: A Randomized, Acute Crossover Study. Can. J. Diabetes 2020, 44, 727–733. [Google Scholar] [CrossRef]
  63. Schmidt, M.I.; Hadji-Georgopoulos, A.; Rendell, M.; Margolis, S.; Kowarski, A. The Dawn Phenomenon, an Early Morning Glucose Rise: Implications for Diabetic Intraday Blood Glucose Variation. Diabetes Care 1981, 4, 579–585. [Google Scholar] [CrossRef]
  64. Edge, J.A. , Matthews, D.R.; Dunger, D.B. The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics. Clin Endocrinol 1990, 33, 729–737. [Google Scholar] [CrossRef]
  65. Cockcroft, E.J.; Moudiotis, C.; Kitchen, J.; Bond, B.; Williams, C.A.; Barker, A.R. High-intensity interval exercise and glycemic control in adolescents with type one diabetes mellitus: a case study. Physiological reports 2017, 5, e13339. [Google Scholar] [CrossRef]
  66. Gallen, I.W.; Hume, C.; Lumb, A. Fuelling the athlete with type 1 diabetes. Diabetes, Obes. Metab. 2010, 13, 130–136. [Google Scholar] [CrossRef]
  67. Chu, L.; Hamilton, J.; Riddell, M.C. Clinical Management of the Physically Active Patient with Type 1 Diabetes. Physician Sportsmed. 2011, 39, 64–77. [Google Scholar] [CrossRef]
  68. Khaw, K.-T.; Wareham, N.; Luben, R.; Bingham, S.; Oakes, S.; Welch, A.; Day, N. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001, 322, 15–15. [Google Scholar] [CrossRef]
  69. Chiavaroli, L.; Lee, D.; Ahmed, A.; Cheung, A.; A Khan, T.; Blanco, S.; Mejia; Mirrahimi, A.; A Jenkins, D.J.; Livesey, G.; et al. Effect of low glycaemic index or load dietary patterns on glycaemic control and cardiometabolic risk factors in diabetes: systematic review and meta-analysis of randomised controlled trials. BMJ 2021, 374, n1651. [Google Scholar] [CrossRef] [PubMed]
  70. Jenkins, D.J.A.; Kendall, C.W.C.; Augustin, L.S.A.; Mitchell, S.; Sahye-Pudaruth, S.; Mejia, S.B.; Chiavaroli, L.; Mirrahimi, A.; Ireland, C.; Bashyam, B.; et al. Effect of Legumes as Part of a Low Glycemic Index Diet on Glycemic Control and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus. JAMA Intern. Med. 2012, 172, 1653–1660. [Google Scholar] [CrossRef] [PubMed]
  71. Giacco, R.; Parillo, M.; A Rivellese, A.; Lasorella, G.; Giacco, A.; D'Episcopo, L.; Riccardi, G. Long-term dietary treatment with increased amounts of fiber-rich low-glycemic index natural foods improves blood glucose control and reduces the number of hypoglycemic events in type 1 diabetic patients. Diabetes Care 2000, 23, 1461–1466. [Google Scholar] [CrossRef] [PubMed]
  72. Mann, J.I.; De Leeuw, I.; Hermansen, K.; Karamanos, B.; Karlström, B.; Katsilambros, N.; Riccardi, G.; Rivellese, A.A.; Rizkalla, S.; Slama, G.; et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr. Metab. Cardiovasc. Dis. 2004, 14, 373–394. [Google Scholar] [CrossRef]
  73. Khosravi-Boroujeni, H.; Mohammadifard, N.; Sarrafzadegan, N.; Sajjadi, F.; Maghroun, M.; Khosravi, A.; Alikhasi, H.; Rafieian, M.; Azadbakht, L. Potato consumption and cardiovascular disease risk factors among Iranian population. Int. J. Food Sci. Nutr. 2012, 63, 913–920. [Google Scholar] [CrossRef]
  74. Blaak, E.E.; Antoine, J.-M.; Benton, D.; Björck, I.; Bozzetto, L.; Brouns, F.; Diamant, M.; Dye, L.; Hulshof, T.; Holst, J.J.; et al. Impact of postprandial glycaemia on health and prevention of disease. Obes. Rev. 2012, 13, 923–984. [Google Scholar] [CrossRef]
  75. Gray, A.; Threlkeld, R.J. Nutritional Recommendations for Individuals with Diabetes. [Updated 2019 Oct 13]. In Endotext [Internet]; Feingold, K.R., Anawalt, B., Blackman, M.R., Eds.; MDText.com, Inc.: South Dartmouth, MA, USA, 2790; Available online: https://www.ncbi.nlm.nih.gov/books/NBK279012/.
  76. Franz, M.J.; Boucher, J.L.; Evert, A.B. Evidence-based diabetes nutrition therapy recommendations are effective: the key is individualization. Diabetes, Metab. Syndr. Obesity: Targets Ther. 2014, 7, 65–72. [Google Scholar] [CrossRef]
  77. EFSA (European Food Safety Authority). Dietary Reference Values for Nutrients Summary Report. EFSA Support. Public. 2017, 14, e15121. [CrossRef]
  78. Martínez-González, M.A.; Salas-Salvadó, J.; Estruch, R.; Corella, D.; Fitó, M.; Ros, E.; Predimed Investigators. Benefits of the Mediterranean Diet: Insights From the PREDIMED Study. Prog. Cardiovasc. Dis. 2015, 58, 50–60. [Google Scholar] [CrossRef] [PubMed]
  79. American Diabetes Association. 5. Lifestyle Management: Standards of Medical Care in Diabetes—2019. Diabetes Care 2019, 42 (Suppl. 1), S46–S60. [Google Scholar] [CrossRef] [PubMed]
  80. Nuttall, F.Q.; Gannon, M.C. Metabolic response of people with type 2 diabetes to a high protein diet. Nutr. Metab. 2004, 1, 6–6. [Google Scholar] [CrossRef] [PubMed]
  81. Turton, J.L.; Struik, N.A.; Riley, M.; Brinkworth, G.D. Adults with and without type 1 diabetes have similar energy and macronutrient intakes: an analysis from the Australian Health Survey 2011-2013. Nutr. Res. 2020, 84, 25–32. [Google Scholar] [CrossRef]
  82. National Kidney Foundation. KDOQI clinical practice guidelines for diabetes and chronic kidney disease. Am J Kidney Dis 2012, 49 (Suppl. 2), S1–S179. [Google Scholar]
  83. Food and Nutrition Board. Proteins and Amino Acids. In Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids; The National Academies Press: Washington, DC, USA, 2005; pp. 589–768. [Google Scholar]
  84. Huang, L.E.; Arany, Z.; Livingston, D.M.; et al. Activation of hypoxia-inducible transcription factor depends primarily upon re-dox-sensitive stabilization of its alpha subunit. J Biol Chem 1996, 271, 32253–32259. [Google Scholar] [CrossRef] [PubMed]
  85. Żebrowska, A.; Jastrzębski, D.; Sadowska-Krępa, E.; Sikora, M.; Di Giulio, C. Comparison of the Effectiveness of High-Intensity Interval Training in Hypoxia and Normoxia in Healthy Male Volunteers: A Pilot Study. BioMed Res. Int. 2019, 2019, 1–10. [Google Scholar] [CrossRef]
  86. Xing, J.; Lu, J. HIF-1α Activation Attenuates IL-6 and TNF-α Pathways in Hippocampus of Rats Following Transient Global Ischemia. Cell. Physiol. Biochem. 2016, 39, 511–520. [Google Scholar] [CrossRef]
  87. Li, G.; Lu, W.-H.; Ai, R.; Yang, J.-H.; Chen, F.; Tang, Z.-Z. The relationship between serum hypoxia-inducible factor 1α and coronary artery calcification in asymptomatic type 2 diabetic patients. Cardiovasc. Diabetol. 2014, 13, 52. [Google Scholar] [CrossRef] [PubMed]
  88. Rusdiana, R.; Moradi, A.; Widjaja, S.; Sari, M.; Hidayat, H.; Savira, M.; Amelia, R.; Rusmalawaty, R. The Effect of Hypoxia Inducible Factor -1 Alpha and Vascular Endothelial Growth Factor Level in Type 2 Diabetes Microvascular Complications and Development. Med Arch. 2022, 76, 135–139. [Google Scholar] [CrossRef] [PubMed]
  89. Xiao, H.; Gu, Z.; Wang, G.; Zhao, T. The Possible Mechanisms Underlying the Impairment of HIF-1α Pathway Signaling in Hyperglycemia and the Beneficial Effects of Certain Therapies. Int. J. Med Sci. 2013, 10, 1412–1421. [Google Scholar] [CrossRef]
  90. Catrina, S.-B.; Okamoto, K.; Pereira, T.; Brismar, K.; Poellinger, L. Hyperglycemia Regulates Hypoxia-Inducible Factor-1α Protein Stability and Function. Diabetes 2004, 53, 3226–3232. [Google Scholar] [CrossRef]
  91. Thangarajah, H.; Vial, I.N.; Grogan, R.H.; Yao, D.; Shi, Y.; Januszyk, M.; Galiano, R.D.; Chang, E.I.; Galvez, M.G.; Glotzbach, J.P.; et al. HIF-1α dysfunction in diabetes. 2010, 9, 75–79. Cell cycle 2010, 9, 75–79. [Google Scholar] [CrossRef] [PubMed]
  92. Ahluwalia, A.; Tarnawski, A.S. Critical Role of Hypoxia Sensor - HIF-1α in VEGF Gene Activation. Implications for Angiogenesis and Tissue Injury Healing. Curr. Med. Chem. 2012, 19, 90–97. [Google Scholar] [CrossRef] [PubMed]
  93. Brown, M.D.; Hudlicka, O. Modulation of physiological angiogenesis in skeletal muscle by mechanical forces: Involvement of VEGF and metalloproteinases. Angiogenesis 2003, 6, 1–14. [Google Scholar] [CrossRef]
  94. Shoag, J.; Arany, Z. Regulation of Hypoxia-Inducible Genes by PGC-1α. Arter. Thromb. Vasc. Biol. 2010, 30, 662–666. [Google Scholar] [CrossRef]
  95. Martin, A.; Komada, M.R.; Sane, D.C. Abnormal angiogenesis in diabetes mellitus. Med. Res. Rev. 2003, 23, 117–145. [Google Scholar] [CrossRef]
  96. Tooke, J.E. Microvasculature in diabetes. Cardiovasc Res 1996, 32, 764–71. [Google Scholar] [CrossRef]
  97. Waltenberger, J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc. Res. 2001, 49, 554–560. [Google Scholar] [CrossRef]
  98. Petersen, A.M.W.; Pedersen, B.K. The anti-inflammatory effect of exercise. J. Appl. Physiol. 2005, 98, 1154–1162. [Google Scholar] [CrossRef]
  99. Giraudo, E.; Primo, L.; Audero, E.; Gerber, H.-P.; Koolwijk, P.; Soker, S.; Klagsbrun, M.; Ferrara, N.; Bussolino, F. Tumor Necrosis Factor-α Regulates Expression of Vascular Endothelial Growth Factor Receptor-2 and of Its Co-receptor Neuropilin-1 in Human Vascular Endothelial Cells. J. Biol. Chem. 1998, 273, 22128–22135. [Google Scholar] [CrossRef] [PubMed]
  100. A Febbraio, M.; Steensberg, A.; Starkie, R.L.; McConell, G.K.; A Kingwell, B. Skeletal muscle interleukin-6 and tumor necrosis factor-α release in healthy subjects and patients with type 2 diabetes at rest and during exercise. Metabolism 2003, 52, 939–944. [Google Scholar] [CrossRef] [PubMed]
  101. Quarta, S.; Massaro, M.; Carluccio, M.A.; Calabriso, N.; Bravo, L.; Sarria, B.; García-Conesa, M.-T. An Exploratory Critical Review on TNF-α as a Potential Inflammatory Biomarker Responsive to Dietary Intervention with Bioactive Foods and Derived Products. Foods 2022, 11, 2524. [Google Scholar] [CrossRef]
  102. Kurtovic, N.; Halilovic, E. Serum Levels of Tumor Necrosis Factor - alpha in Patients With Psoriasis. Mater. Socio Medica 2022, 34, 40–43. [Google Scholar] [CrossRef]
  103. Feuerer, M.; Herrero, L.; Cipolletta, D.; Naaz, A.; Wong, J.; Nayer, A.; Lee, J.; Goldfine, A.B.; Benoist, C.; Shoelson, S.; et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 2009, 15, 930–939. [Google Scholar] [CrossRef]
Preprints 81688 g001
Figure 1. The research project’s exercise protocol. Stage 1 – participants performed a graded exercise test; Stage 2 – participants performed a moderate intensity continuous exercise test; Stage 3 – participants performed a high intensity interval exercise test (HIIE). All exercise tests were performed in normoxia and normobaric hypoxia (FiO₂ = 15.1%). The present paper describes the results of the intermittent exercise test (HIIE) in normoxia only (Stage 3).
Figure 1. The research project’s exercise protocol. Stage 1 – participants performed a graded exercise test; Stage 2 – participants performed a moderate intensity continuous exercise test; Stage 3 – participants performed a high intensity interval exercise test (HIIE). All exercise tests were performed in normoxia and normobaric hypoxia (FiO₂ = 15.1%). The present paper describes the results of the intermittent exercise test (HIIE) in normoxia only (Stage 3).
Preprints 81688 g001
Preprints 81688 g002
Figure 2. Serum blood glucose level at rest, immediately after and at 24-h of post-exercise period in the T1D and control group.
Figure 2. Serum blood glucose level at rest, immediately after and at 24-h of post-exercise period in the T1D and control group.
Preprints 81688 g002
Table 1. Somatic and physiological characteristics, and macronutrients intake of the studied groups.
Table 1. Somatic and physiological characteristics, and macronutrients intake of the studied groups.
T1D group n = 9 (female n = 2) Control group n = 9 (female n = 3)
Mean ±SD Min max Mean ±SD min max
Age 30.2 10.9 18.0 43.0 22.4 1.4 21.0 26.0
Body mass [kg] 74.8 14.3 51.1 99.1 70.1 9.2 58.3 91.5
Body height [m] 1.8 0.1 1.6 1.9 1.7 0.1 1.6 1.8
BMI 23.8 3.6 18.1 29.9 23.5 2.5 19.9 27.9
%BF 17.5 8.3 6.5 33.5 18.7 6.3 10.1 26.4
FFM [kg] 61.6 12.6 41.6 75.3 56.9 8.3 43.4 70.0
V̇O₂peak (ml/kg/min) 39.0 8.2 31.0 48.0 47.8 11.1 30.0 69.0
T1D duration [years] 12.3 9.1 4.0 27.0 n.a. n.a. n.a. n.a.
HbA1C [%] 7.3 0.8 6.1 8.8 n.m. n.m. n.m. n.m.
Energy intake [kcal/day] 2153.7 739.1 1076 3243 2778.6 769.1 2174.7 4408.9
CHO intake [g/day] 241.3 98.2 113.7 365.5 353.2 146.9 250.4 663.6
CHO %energy intake 54.0 10.3 41.2 70.8 60.4 6.9 48.5 70.0
Protein intake [g/day] 116.2 58.4 51.2 224.7 111.4 27.6 82.1 159.0
Protein intake [g/kg/day] 1.6 0.8 0.7 2.8 1.6 0.4 1.2 2.2
Protein %energy intake 26.6 9.8 13.5 42.3 20.2 5.6 13.9 30.8
Fat intake [g/day] 86.2 45.0 25.8 152.7 109.2 22.6 76.7 152.1
Fat %energy intake 19.4 7.1 10.3 29.5 19.4 2.2 16.1 22.9
BMI – body mass index; %BF – percentage of body fat; FFM – fat free mass; T1D – type 1 diabetes; HbA1C – glycated haemoglobin; CHO – carbohydrates; n.a. – not applicable; n.m. – not measured.
Table 2. Fasting glycaemia, insulin administration and digestible carbohydrates intake on the day of (day 1) and the day after (day 2) completion of HIIE in T1D group.
Table 2. Fasting glycaemia, insulin administration and digestible carbohydrates intake on the day of (day 1) and the day after (day 2) completion of HIIE in T1D group.
Variables T1D group
Mean SD
Fasting glycaemia day 1 [mg/dL] 164.5 78.5
Fasting glycaemia day 2 [mg/dL] 139.0 9.9
Insulin day 1 [units/day] 35.3 10.9
Insulin day 2 [units/day] 34.5 13.5
Digestible CHO day 1 157.0 104.2
Digestible CHO day 2 190.5 57.7
Table 3. Serum levels of the transcription factor HIF-1α and pro-inflammatory cytokines (TNF-α and VEGF) in response to HIIE in the T1D and control group.
Table 3. Serum levels of the transcription factor HIF-1α and pro-inflammatory cytokines (TNF-α and VEGF) in response to HIIE in the T1D and control group.
Variables T1D group Control group T1D group Control group
%change: rest vs max %change: rest vs 24-h %change: rest vs max %change: rest vs 24-h
Mean ±SD Mean ±SD
HIF-1α rest [ng/mL] 657.0*** 210.4 28.3 11.5 34.4%↓ 39.1%↓ 278.9%↑ 242.7%↑
HIF-1α max [ng/mL] 430.0 163.3 107.0 56.9
HIF-1α 24-h [ng/mL] 399.5 297.7 96.8 76.9
TNF-α rest [pg/mL] 17.6 19.4 37.8 13.0 111.0%↑ 123.1%↑ 26.3%↓ 44.3%↓
TNF-α max [pg/mL] 37.2 9.3 27.7 10.3
TNF-α 24-h [pg/mL] 39.3 16.5 20.9 9.5
VEGF rest [pg/mL] 7.3 4.6 16.2 4.6 310.3%↑ 103.4%↑ 62.9%↓ 61.4%↓
VEGF max [pg/mL] 30.0* 25.3 6.1 3.4
VEGF 24-h [pg/mL] 14.9 3.1 6.3 3.20
Max – immediately after HIIE; 24-h – 24 hours after HIIE. *p <0.05, *** p<0.001 – significant difference between the T1D group and control group.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated